Abstract
Clinical trials are considered the gold standard for biomedical research, and they are the preferred method to support the safety and efficacy evaluation of medical products and devices. However, safety and effectiveness can vary substantially among different subgroups of a target population according to both intrinsic and extrinsic factors, such as age, sex, gender, race, ethnicity, lifestyle, and location. Moreover, some groups continue to be inconsistently included in clinical trials based on their representation in the total afflicted population, which demands serious resolution. From literature review, this article imparts several possible strategies to overcome obstacles in clinical trial access and enrichment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
